Stacey Stein, MD, is an associate professor of internal medicine and the assistant medical director of the Clinical Trials Office at Yale School of Medicine.
Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC
Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.